A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII

Dimitri G. Trembath, Anita Lal, David J. Kroll, Nicholas H. Oberlies, Gregory J Riggins

Research output: Contribution to journalArticle

Abstract

Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells without EGFRvIII as a control. Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829, which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but permitted normal growth of matched control cells. NSC-154829 had no previously established medicinal use, but has a purine-like structural component. Further experiments showed this compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of p21, independent of any changes in p53 levels or in Akt phosphorylation. Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be further investigated for its potential as an anti-glioblastoma drug, although its precise molecular mechanism is still undefined.

Original languageEnglish (US)
Article number30
JournalMolecular Cancer
Volume6
DOIs
StatePublished - Apr 16 2007

Fingerprint

Glioblastoma
Cells
Molecules
Epidermal Growth Factor Receptor
Mutation
Phosphorylation
Sequence Deletion
Growth
Neoplasms
epidermal growth factor receptor VIII
Apoptosis
Therapeutics
Pharmaceutical Preparations
Experiments

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Cancer Research
  • Molecular Medicine

Cite this

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. / Trembath, Dimitri G.; Lal, Anita; Kroll, David J.; Oberlies, Nicholas H.; Riggins, Gregory J.

In: Molecular Cancer, Vol. 6, 30, 16.04.2007.

Research output: Contribution to journalArticle

Trembath, Dimitri G. ; Lal, Anita ; Kroll, David J. ; Oberlies, Nicholas H. ; Riggins, Gregory J. / A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. In: Molecular Cancer. 2007 ; Vol. 6.
@article{3c159cbfa73a4fc8aa001d1dcfce9e2e,
title = "A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII",
abstract = "Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40{\%} of glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells without EGFRvIII as a control. Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829, which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but permitted normal growth of matched control cells. NSC-154829 had no previously established medicinal use, but has a purine-like structural component. Further experiments showed this compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of p21, independent of any changes in p53 levels or in Akt phosphorylation. Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be further investigated for its potential as an anti-glioblastoma drug, although its precise molecular mechanism is still undefined.",
author = "Trembath, {Dimitri G.} and Anita Lal and Kroll, {David J.} and Oberlies, {Nicholas H.} and Riggins, {Gregory J}",
year = "2007",
month = "4",
day = "16",
doi = "10.1186/1476-4598-6-30",
language = "English (US)",
volume = "6",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII

AU - Trembath, Dimitri G.

AU - Lal, Anita

AU - Kroll, David J.

AU - Oberlies, Nicholas H.

AU - Riggins, Gregory J

PY - 2007/4/16

Y1 - 2007/4/16

N2 - Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells without EGFRvIII as a control. Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829, which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but permitted normal growth of matched control cells. NSC-154829 had no previously established medicinal use, but has a purine-like structural component. Further experiments showed this compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of p21, independent of any changes in p53 levels or in Akt phosphorylation. Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be further investigated for its potential as an anti-glioblastoma drug, although its precise molecular mechanism is still undefined.

AB - Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells without EGFRvIII as a control. Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829, which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but permitted normal growth of matched control cells. NSC-154829 had no previously established medicinal use, but has a purine-like structural component. Further experiments showed this compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of p21, independent of any changes in p53 levels or in Akt phosphorylation. Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be further investigated for its potential as an anti-glioblastoma drug, although its precise molecular mechanism is still undefined.

UR - http://www.scopus.com/inward/record.url?scp=34247543390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247543390&partnerID=8YFLogxK

U2 - 10.1186/1476-4598-6-30

DO - 10.1186/1476-4598-6-30

M3 - Article

VL - 6

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

M1 - 30

ER -